Thromboembolic complications and haemostatic changes in cyclosporin-treated cadaveric kidney allograft recipients.
The incidence of thromboembolic complications was compared retrospectively in 90 cadaveric kidney allograft recipients treated with cyclosporin and low-dose steroids and the same number of cadaveric kidney allograft recipients treated with azathioprine, antilymphocyte globulin, and high-dose steroids. In the cyclosporin group, 17 thromboembolic complications occurred in 13 patients: 10 pulmonary emboli, 1 renal vein thrombosis, 3 deep vein thromboses, and 3 haemorrhoidal thromboses. In the azathioprine group, the only thromboembolic complication was 1 episode of superficial thrombophlebitis. Haemostatic tests in cyclosporin-treated and azathioprine-treated patients and normal subjects (10 in each group) showed increased concentrations of factor VIII C, fibrinogen, antithrombin III, and protein C in the cyclosporin-treated patients. Adenosine-5'-diphosphate-induced platelet aggregation was also significantly enhanced in the cyclosporin group. The effect of cyclosporin on haemostasis may predispose to thromboembolic complications.
Vanrenterghem
Y
Y
Roels
L
L
Lerut
T
T
Gruwez
J
J
Michielsen
P
P
Gresele
P
P
Deckmyn
H
H
Colucci
M
M
Arnout
J
J
Vermylen
J
J
D001379:Azathioprine / Q000009:adverse effects / Q000627:therapeutic use; D001779:Blood Coagulation Factors / Q000032:analysis; D001780:Blood Coagulation Tests; D003524:Cyclosporins / Q000009:adverse effects* / Q000627:therapeutic use; D006487:Hemostasis / Q000187:drug effects*; D006801:Humans; D007165:Immunosuppression Therapy; D016030:Kidney Transplantation; D010974:Platelet Aggregation / Q000187:drug effects; D013923:Thromboembolism / Q000097:blood / Q000139:chemically induced*
D001779:Blood Coagulation Factors; D003524:Cyclosporins; D001379:Azathioprine